

Impact of Congestive Heart Failure on Postoperative Outcomes of Primary Total Knee Arthroplasty: A NSQIP Analysis between 2008 and 2016

Eric Howard Tischler, Ryan Kong, Juhayer S Alam, FAISAL ELALI, David H Mai, Chibuokem Prince Ikwuazom, Nicholas Stekas¹, Jaydev B Mistry², Qais Naziri³

¹SUNY Downstate, ²SUNY Downstate Medical Center, ³SUNY DOWNSTATE MEDICAL CENTER

INTRODUCTION: Total knee arthroplasty (TKA) is a commonly performed procedure in elderly patients due to arthritis or other causes of chronic disability. Due to an elderly patient population, congestive heart failure (CHF) is a common comorbidity. Currently, there is a paucity of data on the impact of CHF on postoperative TKA outcomes. This study aims to identify patient demographics and postoperative outcomes in patients with CHF undergoing TKA.

METHODS: The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database was queried via CPT codes between 2008 and 2016 for patients undergoing TKA (CPT code 27447). CHF status was identified via the "HXCHF" variable in the database. 1:1 propensity score matching controlled for gender, age, BMI and estimated morbidity probability. Patient demographics, comorbidities, and 30-day postoperative outcomes were compared using univariate analysis. Binary logistic regression models were used to identify congestive heart failure as a risk factor for adverse postoperative outcomes after TKA.

RESULTS: 225,475 patients that underwent TKA between 2008 and 2016 were identified (623 with CHF, 224,852 without CHF). Using 1:1 propensity score matching, 559 patients with and without CHF were identified. 62.1% of patients were female and 88.3% were white (Table 1). Average patient age was 66.6 ± 9.6, with an average body mass index (BMI) of 33.0 ± 7.0. Patients stayed at the hospital an average of 3.0 ± 3.2 days. A large majority, 98.5%, of patients were independent prior to surgery. 19,291 (8.6%) of patients smoked. The most common comorbidities identified were hypertension requiring medication (147923 patients, 65.6%), diabetes (40734, 18.1%), and anemia (40640, 18.0%). 26,999 patients (12.0%) experienced any kind of adverse event. The most common postoperative complications identified were wound complications (16526, 7.3%) followed by cardiac complications (2601, 1.2%). 6,556 (2.9%) of patients required readmission and 2,370 (1.1%) required reoperation. There was a 0.1% mortality rate. Patients with CHF undergoing TKA were more likely to be younger (71.2 vs. 73.2; p<0.001) and have a higher BMI (35.0 vs. 34.1; p=0.046) (Table 2). They also tended to have longer hospital stays (4.2 days vs. 3.4; p=0.003) and had higher estimated probability of both morbidity and mortality (both, p<0.001). Patients with CHF were more likely to be ASA 3 or 4 (93.7% vs. 88.9%; p=0.004), have COPD (19.1% vs. 12.3%; p=0.002), hypertension requiring medication (89.1% vs. 83.9%; p=0.011), or a bleeding disorder (11.3% vs. 7.7%; p=0.041). Using binary logistic regression, CHF was found to be an independent predictor of higher risk for pulmonary complications (OR 2.8), renal complications (OR 2.6), and readmission (OR 1.7) (Table 3). There was no increased risk of cardiac complications (p=0.528), reoperation (p=0.728), or mortality (p=0.068).

DISCUSSION AND CONCLUSION: CHF was found to increase the risk of a number of postoperative complications including pulmonary and renal complications, but not cardiac complications. It was also found to correlate to an increased risk of readmission but not reoperation or mortality. This study can be used to guide clinical decision making in patients with CHF that are undergoing TKA, and risk factors need to be explained to patients pre-operatively based on this knowledge.

Variable	With CHF	Without CHF
Gender		
Female	185	102
Male	138	102
Race		
White	165	102
Black	15	102
Hispanic American or Black	15	102
Asian	15	102
Hispanic American or Asian	15	102
Other	15	102
Age Group		
18-24	15	102
25-34	15	102
35-44	15	102
45-54	15	102
55-64	15	102
65-74	15	102
75-84	15	102
85-94	15	102
95-104	15	102
ASA Class		
1	15	102
2	15	102
3	15	102
4	15	102
5	15	102
6	15	102
7	15	102
8	15	102
9	15	102
10	15	102
11	15	102
12	15	102
13	15	102
14	15	102
15	15	102
16	15	102
17	15	102
18	15	102
19	15	102
20	15	102
21	15	102
22	15	102
23	15	102
24	15	102
25	15	102
26	15	102
27	15	102
28	15	102
29	15	102
30	15	102
31	15	102
32	15	102
33	15	102
34	15	102
35	15	102
36	15	102
37	15	102
38	15	102
39	15	102
40	15	102
41	15	102
42	15	102
43	15	102
44	15	102
45	15	102
46	15	102
47	15	102
48	15	102
49	15	102
50	15	102
51	15	102
52	15	102
53	15	102
54	15	102
55	15	102
56	15	102
57	15	102
58	15	102
59	15	102
60	15	102
61	15	102
62	15	102
63	15	102
64	15	102
65	15	102
66	15	102
67	15	102
68	15	102
69	15	102
70	15	102
71	15	102
72	15	102
73	15	102
74	15	102
75	15	102
76	15	102
77	15	102
78	15	102
79	15	102
80	15	102
81	15	102
82	15	102
83	15	102
84	15	102
85	15	102
86	15	102
87	15	102
88	15	102
89	15	102
90	15	102
91	15	102
92	15	102
93	15	102
94	15	102
95	15	102
96	15	102
97	15	102
98	15	102
99	15	102
100	15	102

Table 1: Demographic Information for Patients With and Without CHF

Postoperative Outcomes	No CHF (N=50)	CHF (N=59)	P-value
Adverse Events	125 (25.4%)	141 (23.8%)	0.261
Any Postoperative Complication	106 (21.0%)	113 (19.0%)	0.598
Wound Complications	86 (17.2%)	79 (13.3%)	0.094
Superficial SSI	5 (1.0%)	8 (1.4%)	0.403
Deep SSI	1 (0.2%)	3 (0.5%)	0.624
Wound Dehiscence	5 (1.0%)	5 (0.9%)	1.000
Bleeding requiring Transfusion	77 (15.4%)	66 (11.2%)	0.325
Pulmonary Complications	7 (1.4%)	19 (3.2%)	0.017
Pneumonia	3 (0.6%)	9 (1.5%)	0.082
Pulmonary Embolism	4 (0.8%)	5 (0.9%)	1.000
Failure to wean (Ventilator > 48 hours)	0 (0.0%)	2 (0.4%)	0.500
Unplanned Intubation	1 (0.2%)	6 (1.0%)	0.124
Renal Complications	8 (1.6%)	20 (3.4%)	0.022
Progressive Renal Insufficiency	3 (0.6%)	0 (0.0%)	0.130
Acute renal failure	0 (0.0%)	3 (0.5%)	0.249
Urinary tract infection	5 (1.0%)	9 (1.5%)	0.282
Neuro Complications (CVA/Stroke)	0 (0.0%)	3 (0.5%)	0.549
Cardiac Complications	10 (2.0%)	13 (2.2%)	0.527
Cardiac arrest	1 (0.2%)	4 (0.7%)	0.374
Myocardial Infarction	1 (0.2%)	6 (1.0%)	0.124
DVT/Thrombophlebitis	8 (1.6%)	3 (0.5%)	0.130
Sepsis-Related Complications	7 (1.4%)	9 (1.5%)	0.615
Sepsis	4 (0.8%)	3 (0.5%)	0.705
Sepsis Shock	0 (0.0%)	3 (0.5%)	0.249
Organ/Space SSI	3 (0.6%)	3 (0.5%)	1.000
Readmission	35 (7.0%)	60 (10.2%)	0.010
Reoperation	16 (3.2%)	18 (3.0%)	0.728
Mortality	1 (0.2%)	7 (1.2%)	0.069

Table 2: Rate of Adverse Postoperative Outcomes Between the CHF and non-CHF Cohorts.

Postoperative Outcomes	OR (95% CI)	P-Value
Adverse Events	1.0 (0.9-1.1)	0.261
Any Postoperative Complication	1.1 (0.8-1.5)	0.598
Wound Complications	0.9 (0.6-1.2)	0.349
Superficial SSI	1.6 (0.5-4.9)	0.407
Deep SSI	3.0 (0.3-29.0)	0.340
Wound Dehiscence	1.0 (0.3-3.5)	1.000
Bleeding Requiring Transfusion	0.8 (0.6-1.3)	0.325
Pulmonary Complications	2.8 (1.2-6.7)	0.022
Pneumonia	3.0 (0.8-11.3)	0.097
Pulmonary Embolism	1.3 (0.3-4.7)	0.738
Failure to Wean (Ventilator > 48 hours)	-	-
Unplanned Intubation	6.1 (0.7-50.5)	0.096
Renal Complications	2.6 (1.1-5.9)	0.026
Progressive Renal Insufficiency	2.7 (0.7-10.2)	0.145
Acute Renal Failure	-	-
Urinary Tract Infection	1.8 (0.6-5.4)	0.289
Neuro Complications (CVA/Stroke)	1.3 (0.6-3.0)	0.528
Cardiac Complications	1.0 (0.4-3.0)	0.528
Cardiac Arrest	4.0 (0.4-36.1)	0.214
Myocardial Infarction	6.1 (0.7-50.4)	0.096
DVT/Thrombophlebitis	0.4 (0.1-1.4)	0.148
Sepsis-Related Complications	1.3 (0.5-3.5)	0.615
Sepsis	0.7 (0.2-3.4)	0.706
Sepsis Shock	-	-
Organ/Space SSI	1.0 (0.2-5.0)	1.000
Readmission	1.7 (1.1-2.7)	0.011
Reoperation	1.1 (0.6-2.0)	0.728
Mortality	7.1 (0.9-57.7)	0.068

Table 3: Odds Ratios of Postoperative Complications in Those With CHF Compared to Those Without